These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 26097562)

  • 1. Carboplatin-docetaxel-induced activity against ovarian cancer is dependent on up-regulated lncRNA PVT1.
    Liu E; Liu Z; Zhou Y
    Int J Clin Exp Pathol; 2015; 8(4):3803-10. PubMed ID: 26097562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased expression of the lncRNA PVT1 promotes tumorigenesis in non-small cell lung cancer.
    Yang YR; Zang SZ; Zhong CL; Li YX; Zhao SS; Feng XJ
    Int J Clin Exp Pathol; 2014; 7(10):6929-35. PubMed ID: 25400777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of Long Noncoding RNA E2F-Mediated Cell Proliferation Enhancing Long Noncoding RNA Is Involved in the Development of Chemoresistance of Cancer Cells to Carboplatin in Ovarian Endometrioid Adenocarcinoma.
    Zhao L; Yang J; Liu X; Fu X; Ding Y; Wang C
    Cancer Biother Radiopharm; 2019 Nov; 34(9):566-571. PubMed ID: 31621389
    [No Abstract]   [Full Text] [Related]  

  • 4. Overexpression of long non-coding RNA PVT1 in gastric cancer cells promotes the development of multidrug resistance.
    Zhang XW; Bu P; Liu L; Zhang XZ; Li J
    Biochem Biophys Res Commun; 2015 Jul; 462(3):227-32. PubMed ID: 25956062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atezolizumab and blockade of LncRNA PVT1 attenuate cisplatin resistant ovarian cancer cells progression synergistically via JAK2/STAT3/PD-L1 pathway.
    Chen Y; Li F; Li D; Liu W; Zhang L
    Clin Immunol; 2021 Jun; 227():108728. PubMed ID: 33878452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ALKBH5 regulates ovarian cancer growth via demethylating long noncoding RNA PVT1 in ovarian cancer.
    Li L; Chen J; Wang A; Yi K
    J Cell Mol Med; 2024 Jan; 28(2):e18066. PubMed ID: 38098223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LncRNA PVT1 predicts prognosis and regulates tumor growth in prostate cancer.
    Yang J; Li C; Mudd A; Gu X
    Biosci Biotechnol Biochem; 2017 Dec; 81(12):2301-2306. PubMed ID: 29050519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting of mutant p53-induced FoxM1 with thiostrepton induces cytotoxicity and enhances carboplatin sensitivity in cancer cells.
    Zhang X; Cheng L; Minn K; Madan R; Godwin AK; Shridhar V; Chien J
    Oncotarget; 2014 Nov; 5(22):11365-80. PubMed ID: 25426548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural immunity enhances the activity of a DR5 agonistic antibody and carboplatin in the treatment of ovarian cancer.
    El-Gazzar A; Perco P; Eckelhart E; Anees M; Sexl V; Mayer B; Liu Y; Mikulits W; Horvat R; Pangerl T; Zheng D; Krainer M
    Mol Cancer Ther; 2010 Apr; 9(4):1007-18. PubMed ID: 20371719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long non-coding RNA PVT1 functions as an oncogene in ovarian cancer via upregulating SOX2.
    Zou MF; Ling J; Wu QY; Zhang CX
    Eur Rev Med Pharmacol Sci; 2018 Nov; 22(21):7183-7188. PubMed ID: 30468460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility study comparing docetaxel-cisplatin versus docetaxel-carboplatin as first-line chemotherapy for ovarian cancer.
    Minagawa Y; Kigawa J; Kanamori Y; Itamochi H; Terakawa N; Okada M; Kitada F
    Gynecol Oncol; 2006 Jun; 101(3):495-8. PubMed ID: 16375950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
    Vasey PA; Jayson GC; Gordon A; Gabra H; Coleman R; Atkinson R; Parkin D; Paul J; Hay A; Kaye SB;
    J Natl Cancer Inst; 2004 Nov; 96(22):1682-91. PubMed ID: 15547181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
    Li X; Wu JB; Chung LW; Huang WC
    Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long non-coding RNA PVT1-5 promotes cell proliferation by regulating miR-126/SLC7A5 axis in lung cancer.
    Li H; Chen S; Liu J; Guo X; Xiang X; Dong T; Ran P; Li Q; Zhu B; Zhang X; Wang D; Xiao C; Zheng S
    Biochem Biophys Res Commun; 2018 Jan; 495(3):2350-2355. PubMed ID: 29277611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PVT1 is a stress-responsive lncRNA that drives ovarian cancer metastasis and chemoresistance.
    Tabury K; Monavarian M; Listik E; Shelton AK; Choi AS; Quintens R; Arend RC; Hempel N; Miller CR; Györrfy B; Mythreye K
    Life Sci Alliance; 2022 Nov; 5(11):. PubMed ID: 35820706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
    Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
    Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Purine Nucleoside Phosphorylase mediated molecular chemotherapy and conventional chemotherapy: a tangible union against chemoresistant cancer.
    Singh PP; Joshi S; Russell PJ; Nair S; Khatri A
    BMC Cancer; 2011 Aug; 11():368. PubMed ID: 21861932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LncRNA PVT1: a Novel Therapeutic Target for Cancers.
    Pan X; Zheng G; Gao C
    Clin Lab; 2018 May; 64(5):655-662. PubMed ID: 29739059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long noncoding RNA PVT1 modulates thyroid cancer cell proliferation by recruiting EZH2 and regulating thyroid-stimulating hormone receptor (TSHR).
    Zhou Q; Chen J; Feng J; Wang J
    Tumour Biol; 2016 Mar; 37(3):3105-13. PubMed ID: 26427660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docetaxel: an alternative taxane in ovarian cancer.
    Katsumata N
    Br J Cancer; 2003 Dec; 89 Suppl 3(Suppl 3):S9-S15. PubMed ID: 14661041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.